Checkpoint Therapeutics (NASDAQ:CKPT) is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is dedicated to advancing a diverse portfolio of immuno-oncology and targeted cancer therapies aiming to address the unmet medical needs of patients. With a strategic approach to drug development, Checkpoint Therapeutics is actively working on bringing innovative cancer treatments through clinical trials with the ultimate goal of improving patient outcomes. Their projects span from early to late-stage clinical trials, focusing on key areas such as non-small cell lung cancer and cutaneous T-cell lymphoma. The objective of Checkpoint Therapeutics is to leverage its expertise to develop and commercialize life-enhancing cancer treatments globally.